I must be slipping!! Have just noticed that Dash Pharma was bought out and is now a holly owned subsidiary of Natco Pharma, effective 1st Jan 2022. Sale price was US$18 million. That's good in one way as Natco is listed on the NY Stock Exchange. So I've had a look at Natco's Jan to March 2022 QTR Financials, but unfortunatly there is no breakdown of revenue streams from subsidiary's nor a break down individual drug products. So I have sent a request to Natco as to where I can obtain this information. Being a public company it should be readily available. I'll keep you all posted. So with all that happens during a takeover I can only hope that the Dash Pharma Team were not distracted too much when it comes to our testosterone interests.
- Forums
- ASX - By Stock
- ACR
- Ann: Acrux announces commercial agreement with Padagis
Ann: Acrux announces commercial agreement with Padagis, page-15
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.31M |
Open | High | Low | Value | Volume |
6.3¢ | 6.4¢ | 6.3¢ | $10.36K | 164.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 83332 | 6.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.4¢ | 4393 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 83332 | 0.060 |
1 | 20000 | 0.059 |
1 | 17241 | 0.058 |
1 | 10000 | 0.055 |
1 | 92500 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.064 | 4393 | 1 |
0.066 | 38550 | 1 |
0.067 | 46144 | 4 |
0.068 | 50000 | 1 |
0.069 | 14507 | 1 |
Last trade - 13.50pm 15/08/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online